Americas

Argentina

Spanish

Brazil

Portuguese

Canada

Chile

Spanish

Colombia

Spanish

Mexico

Spanish

Peru

Spanish

United States

English

Asia Pacific

Europe

Austria

German

Belgium

Czech Republic

Czech

Denmark

Danish

Finland

Finnish

France

French

Germany

German

Greece

Greek

Hungary

Hungarian

Ireland

English

Italy

Italian

Luxembourg

English

Netherlands

Norway

Norwegian

Poland

Polish

Portugal

Portuguese

Romania

Romanian

Spain

Spanish

Sweden

Swedish

Switzerland

United Kingdom

English

Middle East

Israel

Hebrew

Saudi Arabia

Turkey

Turkish

United Arab Emirates

Other

Other Markets

Distributor Markets
Our Medicines
A young woman with grandfather using laptop
News & Perspectives

Every word matters: The next chapter of our Universal Patient Language

Home / Our stories / News & Perspectives / Every word matters: The next chapter of our Universal Patient Language
September 29, 2025

At Bristol Myers Squibb (BMS), we believe that how we communicate can be just as important as what we’re communicating — especially when it comes to people’s health.

Patients often encounter a flood of information along their medical care journey — some of it helpful, much of it overwhelming. Whether they’re reading an educational article online, flipping through a brochure in a waiting room or navigating an informed consent form with their caregiver, the stakes are high and the language is often dense. For many, this creates stress, confusion and hesitation at the very moments when clarity is most needed.

For the past ten years, our Universal Patient Language (UPL) program has worked to make health communication clearer, more empathetic and empowering — removing the barriers that prevent patients from understanding, trusting and acting on the information they’re given.

Why this matters now


Health literacy is more than a communication issue; it’s a public health imperative. Nearly 9 in 10 U.S. adults struggle to understand and use everyday health information. The consequences are staggering: up to 1 million preventable hospital visits each year, 25ドル billion in avoidable costs and an annual national burden estimated as high as 238ドル billion.

"This isn’t just about readability, it’s about responsibility. Universal Patient Language helps us meet patients where they are, at a time when their worlds have been disrupted and clarity is essential. That’s central to how we build equity and earn trust. The clearer we are, the better we serve."
- Andrew Whitehead, vice president and head of Population Health, Bristol Myers Squibb

As the U.S. Centers for Disease Control and Prevention (CDC) has said: "Accurate, accessible and actionable communication is foundational to patient understanding and decisions – and ultimately to prevention and better outcomes."

That’s exactly what UPL aims to deliver.

From toolkit to transformation


What began as a set of communications principles has evolved into an enterprise-wide capability and a driver of meaningful change. Supported by our Global Purpose & Patient Experience team (GP&PE), UPL is now integrated across the entire organization. It’s also backed by a growing community of internal champions within BMS and a comprehensive set of shared tools, including our AI-assisted writing guide and a Cultural Adaptation Toolkit.

This transformation, embedding UPL into everything we do, allows us to drive our efforts to put health in every hand by driving understanding for every patient, no matter who they are, where they live or what they have. UPL, at its core, is anchored to our fundamental belief that every person deserves the opportunity to live a healthy, fulfilling life.

A patient-centered collaboration in action


As UPL continues to evolve, we have been engaging directly with patients to help us test what works, uncover what’s missing and bring clarity into the moments that matter most.

One recent illustration of these collaborations comes from the UPL program’s work with our Patient Engagement & Recruitment (PER) team. Together, they reimagined the core recruitment materials for a recent clinical trial — including the outreach letter, study brochure and visit guide — with a focus on women living with triple-negative breast cancer.

Using UPL principles, these materials were transformed to be clearer, more culturally responsive and emotionally resonant — ensuring the tone, visuals and message would feel personal and empowering.

What patients told us


After the content was revised, it was brought back to patients to gather feedback and understand how the changes landed. They were asked whether they felt more informed, confident and respected and their voices affirmed the shift which shaped our path forward.

Direct patient feedback showed consistent improvement across three dimensions: understanding, confidence and trust. One patient, Atiba, summed it up powerfully:

"I see the thoughtfulness and keeping the ‘human part’ in the conversation. The first review, I could tell people with a scientific background wrote it, but in the second review, I could tell you were talking to me."

Others shared how important it was to see themselves reflected in the imagery and tone. Carol noted:

"Everything in that moment is already a whirlwind. Bring it in, make it concise, make it understandable. This is the first step to healing."

Even across a small sample of interviews, the impact was clear: patients felt more informed, more respected and ready to act.

Where we’re headed next


Looking to the future, BMS plans to invest in tools and teams that help patients understand what’s possible. Because when people understand their choices, they can take part in them. When language includes them, it empowers them.

"At BMS, we believe that patient-centricity is part of our business model. When we make health information understandable, we do more than improve communication. We build trust, empower action and bring science to life in a way that meets people where they are and moves them toward healing."
- Jasmine Greenamyer, vice president, Global Purpose & Patient Experience, Bristol Myers Squibb

That’s the heart of UPL – access, trust and empowerment. It’s how we accelerate helping innovative medicines reach the people who need them, faster and with the compassion, understanding and trust they deserve. To learn more and explore BMS’ open-source UPL tools, visit UPL.org.


Subscribe to Our stories alerts

Beyond just relevant information about Bristol Myers Squibb's therapeutic areas and innovation, Our stories offer a window into the work our employees do every day for patients.


About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.

AltStyle によって変換されたページ (->オリジナル) /